胰腺恶性肿瘤免疫治疗的研究进展
Research Progress of Immunotherapy for Pancreatic Malignant Tumors
DOI: 10.12677/wjcr.2025.152008, PDF,   
作者: 陈思博*：哈密市中心医院检验科，新疆 哈密；衡 阳#：哈密市中心医院肝胆胃肠外科，新疆 哈密
关键词: 胰腺恶性肿瘤；免疫治疗；免疫检查点抑制剂；Pancreatic Malignant Tumor； Immunotherapy； Immune Checkpoint Inhibitors
摘要: 胰腺恶性肿瘤恶性程度高，其死亡率与发病率紧密匹配，尽管近年来的诊疗策略不断进步，但总体预后并没有一个显著的改善。免疫治疗作为新兴的治疗策略，为胰腺恶性肿瘤患者提供了新的治疗思路，并且在部分临床研究中表现出明显的优势。尽管目前仍有诸多局限，但潜力巨大，为胰腺恶性肿瘤患者带来新的曙光。
Abstract: Pancreatic malignant tumors are highly malignant, and their mortality and morbidity are closely matched. Although the diagnosis and treatment strategies have been continuously improved in recent years, the overall prognosis has not been significantly improved. As an emerging treatment strategy, immunotherapy provides new treatment ideas for patients with pancreatic malignant tumors and has shown obvious advantages in some clinical studies. Although there are still many limitations, it has great potential to bring a new dawn to patients with pancreatic cancer.
文章引用：陈思博, 衡阳. 胰腺恶性肿瘤免疫治疗的研究进展[J]. 世界肿瘤研究, 2025, 15(2): 61-66. https://doi.org/10.12677/wjcr.2025.152008

参考文献

[1] Liu, X., Li, Z. and Wang, Y. (2021) Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 5, e1900236. [Google Scholar] [CrossRef] [PubMed]
[2] 刘心悦, 巫燕芬, 马子骞, 等. 胰腺癌患者临床特征及预后分析[J]. 河北医药, 2020, 42(11): 1615-1619.
[3] 刘清华, 张丽, 朱明华药物敏感性试验在胰腺癌化疗药物选择中的作用[J]. 中华胰腺病杂志, 2010, 10(4): 257-259.
[4] Vošmik, M., John, S., Dvořák, J., Mohelníková-Duchoňová, B., Melichar, B., Lohynská, R., et al. (2024) Stereotactic Radiotherapy plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. Oncology and Therapy, 12, 817-831. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, X., Wu, X., Wu, H., Gu, Y., Shao, Y., Shao, Q., et al. (2020) Camrelizumab plus Gemcitabine and Oxaliplatin (GEMOX) in Patients with Advanced Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Trial. Journal for ImmunoTherapy of Cancer, 8, e001240. [Google Scholar] [CrossRef] [PubMed]
[6] Hirano, H., Takahashi, N., Amanuma, Y., Suzuki, N., Takahari, D., Kawakami, T., et al. (2025) Phase II Trial of Nab-Paclitaxel plus Ramucirumab in Combination with Nivolumab for Unresectable Advanced or Recurrent Gastric Cancer after Progression on First-Line Treatment Including Fluoropyrimidine, Platinum, and Anti-PD-1/PD-L1 Antibody (PADDLE). BMC Cancer, 25, Article No. 201. [Google Scholar] [CrossRef] [PubMed]
[7] Ali, L.R., Lenehan, P.J., Cardot-Ruffino, V., Dias Costa, A., Katz, M.H.G., Bauer, T.W., et al. (2023) PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Clinical Cancer Research, 30, 542-553. [Google Scholar] [CrossRef] [PubMed]
[8] Reiss, K.A., Mick, R., Teitelbaum, U., O’Hara, M., Schneider, C., Massa, R., et al. (2022) Niraparib plus Nivolumab or Niraparib plus Ipilimumab in Patients with Platinum-Sensitive Advanced Pancreatic Cancer: A Randomised, Phase 1B/2 Trial. The Lancet Oncology, 23, 1009-1020. [Google Scholar] [CrossRef] [PubMed]
[9] Torphy, R.J., Zhu, Y. and Schulick, R.D. (2018) Immunotherapy for Pancreatic Cancer: Barriers and Breakthroughs. Annals of Gastroenterological Surgery, 2, 274-281. [Google Scholar] [CrossRef] [PubMed]
[10] 赵刚, 潘咏梅, 黄岩松, 等. CAFs与肿瘤细胞的免疫逃逸机制[J]. 中国免疫学杂志, 2023, 39(3): 653-656.
[11] 胡先华. 肿瘤免疫逃逸相关分子及其机制研究进展[J]. 中国医药科学, 2023, 13(8): 36-38.
[12] 向麒颖, 程超, 左长京. 放疗与免疫检查点抑制剂联合治疗肿瘤的研究进展[J]. 国际放射医学核医学杂志, 2023, 47(2): 98-104.
[13] 汝继轩, 吴川林, 张占田, 等. PD-1/PD-L1免疫检查点抑制剂治疗胰腺癌研究进展[J]. 中华胰腺病杂志, 2021, 21(2): 143-147.
[14] Zhong, G., Zhang, X., Zhao, R., Guo, Z., Wang, C., Yu, C., et al. (2025) The High Efficacy of Claudin18.2-Targeted CAR-T Cell Therapy in Advanced Pancreatic Cancer with an Antibody-Dependent Safety Strategy. Molecular Therapy. [Google Scholar] [CrossRef] [PubMed]
[15] Ohta, K., Sakoda, Y., Adachi, K., Shinozaki, T., Nakajima, M., Yasuda, H., et al. (2024) Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Cancer Research Communications, 4, 2514-2524. [Google Scholar] [CrossRef] [PubMed]
[16] Yoon, J.H., Jung, Y. and Moon, S. (2021) Immunotherapy for Pancreatic Cancer. World Journal of Clinical Cases, 9, 2969-2982. [Google Scholar] [CrossRef] [PubMed]
[17] Kabacaoglu, D., Ciecielski, K.J., Ruess, D.A. and Algül, H. (2018) Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 9, Article 1878. [Google Scholar] [CrossRef] [PubMed]
[18] Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., et al. (2020) Immunotherapy for Pancreatic Cancer: A 2020 Update. Cancer Treatment Reviews, 86, Article ID: 102016. [Google Scholar] [CrossRef] [PubMed]
[19] 张凤. PD-1抑制剂联合化疗对比单纯化疗一线治疗晚期胰腺癌的疗效和安全性分析[D]: [硕士学位论文]. 青岛: 青岛大学, 2022.
[20] McDermott, J., and Jimeno, A., (2015) Pembrolizumab: PD-1 Inhibition as a Therapeutic Strategy in Cancer. Drugs of Today, 51, 7-20. [Google Scholar] [CrossRef] [PubMed]
[21] 吴锦, 吕佳忆, 蓝艳, 等. 肿瘤免疫治疗的研究进展[J]. 细胞与分子免疫学杂志, 2019, 35(7): 659-664.

为你推荐